BioTechne Corp (TECH)
(Real Time Quote from BATS)
$62.82 USD
-0.70 (-1.10%)
Updated Apr 25, 2024 01:44 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Techne (TECH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$80.92 | $95.00 | $65.00 | 27.39% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Techne comes to $80.92. The forecasts range from a low of $65.00 to a high of $95.00. The average price target represents an increase of 27.39% from the last closing price of $63.52.
Analyst Price Targets (13)
Broker Rating
Techne currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on 12 recommendations.
Of the 14 recommendations deriving the current ABR, 12 are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 10 | 10 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.33 | 1.33 | 1.36 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
2/9/2024 | Scotiabank | Sung-Ji Nam | Not Available | Strong Buy |
2/2/2024 | The Benchmark Company | Robert Wasserman | Strong Buy | Strong Buy |
2/2/2024 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
2/1/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
2/1/2024 | Craig-Hallum | Alex Nowak | Not Available | Strong Buy |
1/3/2024 | Argus Research Corp. | David A Toung | Not Available | Strong Buy |
11/2/2023 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
8/28/2023 | William Blair | Matt Larew | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 14 |
Average Target Price | $80.92 |
LT Growth Rate | 5.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | 0.46 |